• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.

作者信息

Eşkazan Ahmet Emre

机构信息

Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.

出版信息

Br J Clin Pharmacol. 2020 Sep;86(9):1790-1792. doi: 10.1111/bcp.14353. Epub 2020 May 20.

DOI:10.1111/bcp.14353
PMID:32383276
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7444770/
Abstract
摘要

相似文献

1
Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.慢性髓性白血病与新冠疫情期间酪氨酸激酶抑制剂的使用
Br J Clin Pharmacol. 2020 Sep;86(9):1790-1792. doi: 10.1111/bcp.14353. Epub 2020 May 20.
2
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.甲磺酸伊马替尼用于慢性髓性白血病：一线治疗及长期疗效
Expert Rev Anticancer Ther. 2016;16(3):273-8. doi: 10.1586/14737140.2016.1151356.
3
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.有多少慢性髓系白血病患者能够从诊断进展至深度分子反应并长期停用伊马替尼？一项真实病例经验。
Br J Haematol. 2017 Feb;176(4):669-671. doi: 10.1111/bjh.13983. Epub 2016 Feb 23.
4
Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.伊马替尼——2015年用于慢性髓性白血病一线治疗的新型酪氨酸激酶抑制剂。
JAMA Oncol. 2015 May;1(2):143-4. doi: 10.1001/jamaoncol.2015.50.
5
Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.伊马替尼诱发的慢性髓性白血病患者的银屑病样皮疹。
Am J Hematol. 2018 Mar;93(3):467-468. doi: 10.1002/ajh.24894. Epub 2017 Sep 28.
6
Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.伊马替尼诱发慢性粒细胞白血病患者出现药物超敏反应伴嗜酸性粒细胞增多和全身症状（DRESS）
Leuk Lymphoma. 2017 Feb;58(2):473-474. doi: 10.1080/10428194.2016.1201575. Epub 2016 Jul 7.
7
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.慢性髓性白血病完全细胞遗传学缓解后与伊马替尼相关的骨髓再生障碍
J Coll Physicians Surg Pak. 2008 Mar;18(3):176-8.
8
Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.酪氨酸激酶抑制剂治疗慢性髓性白血病的疗效和安全性比较：系统评价和网络荟萃分析。
Eur J Cancer. 2018 Nov;104:9-20. doi: 10.1016/j.ejca.2018.08.016. Epub 2018 Oct 5.
9
Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.一名慢性髓性白血病分子缓解期患者在伊马替尼治疗期间出现del(20q)，停用伊马替尼后其减少。
Leuk Lymphoma. 2016;57(1):201-2. doi: 10.3109/10428194.2015.1037763. Epub 2015 May 12.
10
Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.慢性髓性白血病患者接受酪氨酸激酶抑制剂治疗后乙型肝炎病毒再激活。
World J Gastroenterol. 2013 Feb 28;19(8):1318-21. doi: 10.3748/wjg.v19.i8.1318.

引用本文的文献

1
COVID-19 in patients with anemia and haematological malignancies: risk factors, clinical guidelines, and emerging therapeutic approaches.COVID-19 与贫血和血液系统恶性肿瘤患者：风险因素、临床指南和新兴治疗方法。
Cell Commun Signal. 2024 Feb 15;22(1):126. doi: 10.1186/s12964-023-01316-9.
2
Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection-A Single Center Survey.慢性髓性白血病合并 COVID-19 感染患者的临床结局：一项单中心调查。
Medicina (Kaunas). 2023 Aug 28;59(9):1564. doi: 10.3390/medicina59091564.
3
What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?目前我们对慢性髓性白血病（CML）和 COVID-19 了解多少？
Curr Oncol Rep. 2022 May;24(5):645-650. doi: 10.1007/s11912-021-01169-w. Epub 2022 Feb 26.
4
COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey.慢性期慢性髓性白血病患者中的新型冠状病毒肺炎：来自土耳其的单中心调查
Turk J Haematol. 2021 Feb 25;38(1):79-81. doi: 10.4274/tjh.galenos.2020.2020.0472. Epub 2020 Sep 23.

本文引用的文献

1
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.氯喹、羟氯喹和阿奇霉素用于治疗新型冠状病毒肺炎（SARS-CoV-2感染）时的安全性考量
CMAJ. 2020 Apr 27;192(17):E450-E453. doi: 10.1503/cmaj.200528. Epub 2020 Apr 8.
2
COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis.COVID-19与癌症：汇总荟萃分析的经验教训
JCO Glob Oncol. 2020 Apr;6:557-559. doi: 10.1200/GO.20.00097.
3
Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?为使慢性髓性白血病患者获得更深的分子反应，联合使用羟氯喹和伊马替尼是否有益？
Leukemia. 2020 Dec;34(12):3426-3427. doi: 10.1038/s41375-020-0796-y. Epub 2020 Mar 13.
4
Discovering drugs to treat coronavirus disease 2019 (COVID-19).发现治疗2019冠状病毒病（COVID-19）的药物。
Drug Discov Ther. 2020;14(1):58-60. doi: 10.5582/ddt.2020.01012.
5
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.
6
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.新型冠状病毒肺炎（SARS-CoV-2）感染的癌症患者：一项中国全国性分析。
Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.
7
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
8
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.一项评估羟氯喹联合伊马替尼对比伊马替尼单药治疗主要细胞遗传学反应后仍有残留疾病的慢性髓性白血病患者的随机 II 期临床试验。
Leukemia. 2020 Jul;34(7):1775-1786. doi: 10.1038/s41375-019-0700-9. Epub 2020 Jan 10.
9
Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?用于治疗慢性髓性白血病的酪氨酸激酶抑制剂（TKIs）与血液学毒性相关 - 哪种TKI最安全？
Br J Clin Pharmacol. 2019 Oct;85(10):2241-2243. doi: 10.1111/bcp.14092. Epub 2019 Aug 22.
10
Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: A network meta-analysis.慢性髓性白血病中酪氨酸激酶抑制剂相关血液学不良事件的网络荟萃分析。
Br J Clin Pharmacol. 2019 Oct;85(10):2280-2291. doi: 10.1111/bcp.13933. Epub 2019 May 23.